Findings from three studies led by researchers at MD Anderson suggest that new combination therapies are safe and effective against various types of leukemia. The investigators believe that the promising data about the use of these therapeutic regimens may lead to new standards of care and more leukemia treatment options. Results from the clinical trials were presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting...
In patients with leukemia, complete remission after treatment is currently defined by the absence of cancer cells in a bone marrow biopsy...
Repurposing FDA-approved therapies is a cost-effective way to bring new treatments to patients in need, but identifying those drugs with benefits...
The addition of nivolumab to induction chemotherapy with idarubicin and cytarabine is feasible in patients with newly diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS), according to findings from a study at The University of Texas MD Anderson Cancer Center.
A study that enrolled 44 patients between August 2015 and June 2018 reported on its findings this month online at The Lancet Haematology. The...
MD Anderson’s Moon Shots Program™ was established to bring teams of world-class clinicians and researchers together in order to rapidly advance...
Tomas Sandoval was about to become a father for the second time in June 2014, when he was devastated to learn he had non-Hodgkin lymphoma...
Natural killer cells sound menacing, but they play a friendly role in keeping us healthy. And they might do much more in stopping...
What if you or a loved one had cancer but were denied access to a research study testing a poten-tially beneficial treatment?
This...